Can J Diabetes 2018 Apr 22;42(2):118-123. Epub 2017 Dec 22.
Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Electronic address:
Download full-text PDF
Can J Diabetes 2018 Apr 22;42(2):124-129. Epub 2017 Dec 22.
Leeds MRC Medical Bioinformatics Centre, University of Leeds, West Yorkshire, United Kingdom.
The renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT) receptor blockers (ARBs) block the binding of ANG II to AT receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. Read More
PLoS Med 2016 Mar 8;13(3):e1001971. Epub 2016 Mar 8.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Background: Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes.
Methods And Findings: Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Read More
J Manag Care Pharm 2011 Oct;17(8 Suppl):S1-14
Duke Division of General Internal Medicine, Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC, USA.
Background: In 2007, the Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review (CER) on the benefits and risks of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) for treating essential hypertension in adults. The main findings indicated that the 2 classes of antihypertensive medications caused similar reductions in blood pressure, although higher rates of adverse events, especially cough, were reported by patients treated with ACEIs. In addition, the 2007 review indicated no treatment related differences in lipid levels, glycemic control, or progression of kidney disease among the agents. Read More
Curr Opin Nephrol Hypertens 2004 May;13(3):319-24
Steno Diabetes Center, Gentofte, Denmark.
Purpose Of Review: Antihypertensive treatment has improved renal prognosis and survival in diabetic nephropathy. The present review summarizes the current status of blockade of the renin-angiotensin system in diabetic nephropathy. Since the current treatment strategies reduce, but do not prevent, the progression of kidney disease, the research focus is directed towards the potential renoprotective effects of dual blockade of the renin-angiotensin system using both angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Read More